• J.P. Morgan Securities and other underwriters in the $82 million initial public offering by CAMP4 Therapeutics Corporation
• J.P. Morgan Securities and other underwriters in the initial public offering and subsequent PIPE financing by Lexeo Therapeutics, Inc., aggregating over $200 million
• Jefferies, J.P. Morgan Securities, and other underwriters in the $130 million follow-on offering and concurrent registered direct offering by ProKidney Corp.
• TD Cowen and WedBush PacGrow in the $100 million follow-on offering by Monte Rosa Therapeutics, Inc.
• Jefferies in the $90 million follow-on offering by Esperion Therapeutics, Inc.
• Leerink Partners in the $80 million follow-on offering by PepGen Inc.
• Piper Sandler and the other placement agents in PIPE financings by Skye Biosciences, Inc., aggregating over $90 million
• Goldman Sachs & Co. LLC and the other underwriters in the $215 million follow-on offering by Syndax Pharmaceuticals, Inc.
• BofA Securities and Goldman Sachs & Co. LLC in the $350 million private placement by Arvinas, Inc.
• Jefferies and Leerink Partners in the $50 million follow-on offering by AC Immune SA
• TD Cowen and other underwriters in the $45 million follow-on offering by Humacyte, Inc.
• Oppenheimer & Co. in the $40 million registered direct offering by Vaxart, Inc.
• Oppenheimer & Co. and Citizens JMP in the $35 million registered direct offering by INOVIO Pharmaceuticals
• Morgan Stanley, J.P. Morgan Securities, Rabo Securities, and other underwriters in the $1.1 billion senior notes offering by AGCO Corporation
• Morgan Stanley, Goldman Sachs, HSBC, Wells Fargo Securities, and other underwriters in the $1.25 billion senior notes offering by Helmerich & Payne
• Wells Fargo, BofA Securities, J.P. Morgan Securities, and other underwriters in the $600 million green bond offering by American Homes 4 Rent
• Varonis Systems, Inc. in its $400 million convertible senior notes offering
• Disc Medicine, Inc. in its reverse merger and follow on offerings aggregating over $290 million in proceeds
• HOOKIPA Pharma Inc. in its follow-on offerings aggregating over $120 million in proceeds
• Goldman Sachs & Co. LLC in the follow-on offering by Taysha Gene Therapies
• Goldman Sachs & Co. LLC and other underwriters in the $140 million follow-on offering by Syndax Pharmaceuticals, Inc.
• Goldman Sachs & Co. LLC and other underwriters in the $102 million follow-on offering by Valneva SE
• J.P. Morgan Securities and other underwriters in the $75 million follow-on offering by Precigen, Inc.

Matters may have been completed before joining Paul Hastings